Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease.

about

Causally treatable, hereditary neuropathies in Fabry's disease, transthyretin-related familial amyloidosis, and Pompe's disease.

Item

http://www.wikidata.org/entity/Q38745211

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Causally treatable, hereditary ...... loidosis, and Pompe's disease.

@en

type

Item

label

Causally treatable, hereditary ...... loidosis, and Pompe's disease.

@en

prefLabel

Causally treatable, hereditary ...... loidosis, and Pompe's disease.

@en

P1476

Causally treatable, hereditary ...... loidosis, and Pompe's disease.

@en

P2093

J Wanschitz

http://www.w3.org/2001/XMLSchema#string

S Iglseder

http://www.w3.org/2001/XMLSchema#string

S Quasthoff

http://www.w3.org/2001/XMLSchema#string

W Grisold

http://www.w3.org/2001/XMLSchema#string

P2860

Enzyme replacement therapy for Anderson-Fabry disease

Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis

Pain management strategies for neuropathic pain in Fabry disease--a systematic review

Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis

Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP

Analysis of voice quality in patients with late-onset Pompe disease.

Unexpected Fabry disease in a renal allograft kidney: an underrecognized cause of poor allograft function.

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

P304

558-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/ANE.12758

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

136

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang Löscher

Josef Finsterer

P577

2017-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28295152

http://www.w3.org/2001/XMLSchema#string